Marco Witteveen

I help startups in medical products, services, and technology go from early-stage spark to global scale. As a senior executive and growth catalyst, I bring strategic clarity, commercialisation expertise, and the ability to rapidly adapt to market shifts. With a track record in business planning, product and market strategy, and global market entry, I’ve partnered […]

Jay Roberts

Jay Roberts has been a senior strategic executive in the healthcare industry for over 30 years. He is a partner with Ventac Partners, a global catalyst in life sciences creating breakthrough companies bringing remarkable scientific innovation to patients worldwide. He also serves as a Venture Partner for DigiLife Fund II, leading fundraising, due diligence and […]

Siham Ceballos

I am a senior biotech and pharma strategist with over 20 years of experience across medical affairs, clinical development, external innovation, portfolio strategy, and venture-facing due diligence. My background spans oncology, hematology, rare diseases, RNA therapeutics, CNS, dermatology, regenerative medicine, and longevity biology. I have held leadership roles in global and regional organizations, including Celgene, […]

Peter Crosby

Peter Crosby is a seasoned medical device industry executive with extensive international leadership experience, having served as Chief Executive Officer for six medical device companies across four countries. He currently runsBiomedical Business Resources LLC, providing strategic advisory services to the biomedical sector. He has served as an expert witness on dozens of cases, with emphasis […]

Wayne Jensen

I’ve spent 30 years in medtech and biotech—from the bench to the production floor to the C-suite—bringing more than 25 products to market across FDA 510(k), CE/MDR, and TGA pathways. I’ve seen exceptional science fail, not because the innovation wasn’t strong, but because the operational, regulatory, and governance foundations weren’t in place to support commercialization. […]

David Browne

I am a marketing & commercial consultant to pharma / biotech companies needing advice and support for success in the UK & EU markets.  I work across the product life cycle from commercial feasibility, go-to-market, marketing & commercial strategy, repositioning mature brands and optimizing portfolios. Deep expertise in commercial and marketing as an experienced Strategic […]

Jeff Spitzner

I am a 12x founder of life sciences technology startups, having raised over $30 million across my portfolio, with both successful exits and ongoing ventures. My companies have spanned biotechnology, software, medical devices, cosmeceuticals, gene therapy, and a venture studio investment platform. My expertise lies in technology commercialization — bringing innovative products from concept to […]

Yoel Bakas, MBA

I am Founder and Managing Director of Medsolve Dynamics, an oncology advisory firm focused on operational strategy, capital alignment, and reimbursement-driven purchasing for radiation oncology programs. I bring 20+ years of executive leadership across oncology technology, including senior roles at Varian, Mevion, ViewRay, and GE HealthCare, working at the intersection of oncology strategy and AI-enabled […]

Francie Barron, PhD

I help biotech companies turn scientific innovation into commercial reality. With a PhD in cell biology and over a decade of business development experience, I bridge the gap between R&D, regulatory strategy, and commercial execution. I’ve closed $4.6M in partnership contracts across life science tools and diagnostics, working with organizations from startups to Fortune 100 […]

Stephanie Astrow, PhD, MBA

Healthcare executive and scientist with 25+ years of leadership in biotechnology, focused on turning scientific innovation into commercial and clinical impact. Proven track record advancing first-in-class therapies and diagnostics, securing FDA clearances, and driving growth across public and private companies—including generating $10M+ in oncology revenue, expanding diagnostic portfolios, and managing a $30M P&L. Currently Chief […]